Canadian Trademark Information

On Wednesday, July 26, 2017, a canadian trademark registration was filed for the above pictured logo by Casebia Therapeutics Limited L *********, **********, ***** ****. The Canadian IP office has given the trademark application number of 1849450. The current status of this trademark filing is Registration published. The trademark is filed in the description of Gene therapy products, namely, therapeutics for the treatment of liver, hepatological, cardiovascular, central nervous system, endocrine, gastrointestinal, immunological, dermatological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmologic, psychiatric, respiratory, urogenital, urological, hematologic, fungal and viral diseases and disorders; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of genetic diseases and disorders , Research and development of human therapeutics using gene editing; pharmaceutical research and development services , Gene therapy products, namely, therapeutic preparations for the treatment of hepatological, namely, liver, gallbladder, and pancreas diseases and disorders, cardiovascular, central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders and spinal cord diseases, endocrine, gastrointestinal, immunological, namely, autoimmune diseases and immunologic deficiency syndromes, dermatological, namely, dermatitis, skin pigmentation diseases, eczema and psoriasis, infectious, namely respiratory infections, eye infections and topical infections, inflammatory, namely, inflammatory bowel diseases, inflammatory connective tissue diseases, menopausal, metabolic, namely, diabetes, hypoglycaemia, gout and anorexia, autoimmune, musculoskeletal, neurological, namely, brain injury, spinal cord injury, seizure disorders, Alzheimer's, Huntington's disease and cerebral palsy, ophthalmologic, psychiatric, namely, mood disorders, anxiety disorders, cognitive disorders and schizophrenia, respiratory, urogenital, urological, hematologic, fungal and viral diseases and disorders, namely, herpes and hepatitis , Gene therapy products, namely, therapeutic preparations for the treatment of hepatological, namely, liver, gallbladder, and pancreas diseases and disorders, cardiovascular, central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders and spinal cord diseases, endocrine, gastrointestinal, immunological, namely, autoimmune diseases and immunologic deficiency syndromes, dermatological, namely, dermatitis, skin pigmentation diseases, eczema and psoriasis, infectious, namely respiratory infections, eye infections and topical infections, inflammatory, namely, inflammatory bowel diseases, inflammatory connective tissue diseases, menopausal, metabolic, namely, diabetes, hypoglycaemia, gout and anorexia, autoimmune, musculoskeletal, neurological, namely, brain injury, spinal cord injury, seizure disorders, Alzheimer's, Huntington's disease and cerebral palsy, ophthalmologic, psychiatric, namely, mood disorders, anxiety disorders, cognitive disorders and schizophrenia, respiratory, urogenital, urological, hematologic, fungal and viral diseases and disorders, namely, herpes and hepatitis , Research and development of human therapeutics using gene editing; pharmaceutical research and development services .